Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

155
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
155
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

131
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
131
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

183
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
183
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

148
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
148
Angina I: Introduction01:30

Angina I: Introduction

194
Definition and Symptoms: Angina (angina pectoris) is chest pain or discomfort caused by myocardial ischemia, which occurs when the heart muscle receives insufficient oxygen-rich blood. It typically manifests as pressing, squeezing, or crushing sensations in the chest and may radiate to the shoulders, arms, neck, jaw, or back.Primary Cause: In a healthy state, the coronary arteries can dilate (widen) to increase blood flow and meet the increased oxygen demand during physical activity or...
194
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

660
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
660

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CRISPR-mediated targeting of the <i>LMNA</i> c.745C>T mutation enhances survival and cardiac function in congenital muscular dystrophy.

Molecular therapy. Advances·2026
Same author

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

NOD1 is a key mediator of atrial myopathy in heart failure.

Theranostics·2026
Same author

Repurposing polyamines to prevent life-threatening arrhythmias in Short QT Syndrome type 3.

Nature communications·2026
Same author

Low-dose Empagliflozin Does Not Modify Myocardial Energetics and Function in a Large-animal Model of Hibernating Myocardium.

Journal of cardiovascular translational research·2026
Same author

Cardiac Surveillance for Anthracycline Cardiotoxicity: Clinical Yield in Low-to-Intermediate Risk Patients: MATRIX Study.

JACC. CardioOncology·2026

Related Experiment Video

Updated: Nov 16, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.1K

Coronary microcirculation damage in anthracycline cardiotoxicity.

Carlos Galán-Arriola1,2, Jean Paul Vílchez-Tschischke1,3, Manuel Lobo1,3

  • 1Centro Nacional de Investigaciones Cardiovasculares (CNIC), c/Melchor Fernández Almagro 3, 28029 Madrid, Spain.

Cardiovascular Research
|February 19, 2021
PubMed
Summary

Anthracycline chemotherapy causes progressive, irreversible microcirculation damage, even at low doses, preceding cardiac dysfunction. This damage may explain cardiovascular events in cancer survivors treated with anthracyclines.

Keywords:
AnthracyclinesCardiac perfusionCardio-oncologyCardiotoxicityCoronary physiologyMicrocirculation

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.6K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.1K

Related Experiment Videos

Last Updated: Nov 16, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.1K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.6K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.1K

Area of Science:

  • Cardiovascular Research
  • Oncology
  • Pharmacology

Background:

  • Anthracyclines are widely used chemotherapy agents.
  • Cardiotoxicity is a known side effect of anthracyclines.
  • The specific impact on coronary microcirculation remains incompletely understood.

Purpose of the Study:

  • To investigate the effects of anthracycline treatment on coronary microcirculation.
  • To assess changes in microcirculation during and after multiple treatment cycles.
  • To correlate microcirculatory changes with cardiac function and structural damage.

Main Methods:

  • Utilized a pig model (n=40) with varying doxorubicin cumulative exposure.
  • Employed serial cardiac magnetic resonance (CMR) for myocardial perfusion assessment.
  • Performed invasive coronary flow reserve (CFR) measurements and ex vivo myography and histology.

Main Results:

  • High-dose anthracyclines caused progressive microcirculation decline, evidenced by reduced perfusion and CFR.
  • Microcirculation damage occurred before contractile defects in high-dose groups.
  • Low-dose anthracyclines induced persistent microcirculation damage and structural arterial damage without contractile deficits.

Conclusions:

  • Anthracycline treatment leads to progressive and irreversible coronary microcirculation damage.
  • Microcirculation impairment persists even at low cumulative doses, independent of contractile function.
  • This microcirculation damage may contribute to cardiovascular events in cancer survivors.